GlassScriptPhysician profile
Kristan M Devine
NPI 1659303923
$3,472.28
in general payments reported to CMS, 2019-2025
32 companies · $962 in 2025
The $962 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.27 · 2022: $553 · 2023: $897 · 2024: $1,039 · 2025: $962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,897.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $592.49 | 2023-2025 | Floseal, Perclot, Tisseel |
| Abiomed | $404.84 | 2022-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $363.26 | 2022-2025 | Lifevest |
| Abbott Laboratories | $338.91 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Navitor |
| Merck Sharp & Dohme LLC | $242.65 | 2022-2025 | Verquvo |
| Atricure, INC. | $183.82 | 2022-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Janssen Pharmaceuticals, INC | $127.10 | 2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $121.03 | 2024-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $115.03 | 2025 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $112.18 | 2023-2025 | Wainua, Brilinta, Farxiga |
| Boston Scientific Corporation | $96.10 | 2023 | Watchman Access System |
| Medtronic, INC. | $90.86 | 2021-2025 | Corevalve Evolut R |
| Novartis Pharmaceuticals Corporation | $82.00 | 2023-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $62.99 | 2023 | Arcalyst |
| La Jolla Pharmaceutical Company | $59.11 | 2024-2025 | Giapreza |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $57.35 | 2023-2024 | Prolene, Surgicel Nu-Knit, Ethicon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.46 | 2024-2025 | Jardiance |
| Edwards Lifesciences Corporation | $51.83 | 2022-2023 | |
| Livanova USA, INC. | $49.33 | 2022-2023 | Protekduo |
| Paladin Technology Solutions | $30.78 | 2024-2025 | |
| Medicomp INC | $29.40 | 2024 | Telepatch Cardiac Monitor |
| Actelion Pharmaceuticals US, INC. | $25.93 | 2022 | |
| Impulse Dynamics (USA) INC. | $23.48 | 2023 | Optimizer |
| Lexicon Pharmaceuticals, INC. | $20.28 | 2023 | Inpefa |
| Novo Nordisk INC | $20.05 | 2024 | Ozempic, Rybelsus |
| Kiniksa Pharmaceuticals International, Plc | $18.51 | 2024 | Arcalyst |
| Watermark Medical, INC. | $18.02 | 2025 | |
| Cvrx, INC. | $17.82 | 2025 | Barostim Neo System |
| Bard Peripheral Vascular, INC. | $17.24 | 2025 | Lutonix Drug Coated Balloon |
| Avanos Medical | $16.07 | 2022 | |
| Bridgebio Pharma, INC. | $15.29 | 2025 | Attruby |
| Pfizer INC. | $15.07 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristan Devine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.